1
|
Liu Y, Lyu K, Liu S, You J, Wang X, Wang M, Zhang D, Bai Y, Yin C, Jiang M, Zheng S. Predictive value of total cholesterol to high-density lipoprotein cholesterol ratio for chronic kidney disease among adult male and female in Northwest China. Chronic Dis Transl Med 2024; 10:216-226. [PMID: 39027193 PMCID: PMC11252436 DOI: 10.1002/cdt3.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Revised: 03/12/2024] [Accepted: 03/27/2024] [Indexed: 07/20/2024] Open
Abstract
Background Studies have found that the ratio of total cholesterol to high-density lipoprotein cholesterol (TC/HDL-C) was associated with the development of chronic kidney disease (CKD). However, the relationship in different genders was rarely discussed. The aim of this study was to explore this relationship and assess its predictive power for both males and females. Methods Based on a prospective cohort platform in northwest China, 32,351 participants without CKD were collected in the baseline and followed up for approximately 5 years. Cox proportional hazard model and restricted cubic spline regression analysis were performed to investigate the association between TC, HDL-C, TC/HDL-C and CKD in adult female and male. The clinical application value of the indicators in predicting CKD was evaluated by the receiver operator characteristic curve. Results During a mean follow-up of 2.2 years, 484 males and 164 females developed CKD. After adjusted for relevant confounders, for every one standard deviation increase in TC, HDL-C and TC/HDL-C, the hazard ratios (HRs) and 95% confidence intervals (95% CIs) for CKD were 1.17 (1.05-1.31), 0.84 (0.71-0.99), and 1.15 (1.06-1.25) for males, 0.94 (0.78-1.13), 0.58 (0.35-0.95), and 1.19 (1.01-1.40) for females, respectively. The results also showed that TC, HDL-C, and TC/HDL-C were associated with CKD in a linear dose-response relationship. The TC/HDL-C had the largest area under the curve (AUC) compared to TC and HDL-C, and the AUC among the females was larger than that among males. Conclusions The TC/HDL-C was significantly associated with CKD in adult males and females and has better clinical value in predicting CKD than TC and HDL-C, especially in females.
Collapse
Affiliation(s)
- Yanli Liu
- School of Public Health, Institute of Epidemiology and StatisticsLanzhou UniversityLanzhouGansuChina
| | - Kang Lyu
- School of Public Health, Institute of Epidemiology and StatisticsLanzhou UniversityLanzhouGansuChina
| | - Shaodong Liu
- School of Public Health, Institute of Epidemiology and StatisticsLanzhou UniversityLanzhouGansuChina
| | - Jinlong You
- School of Public Health, Institute of Epidemiology and StatisticsLanzhou UniversityLanzhouGansuChina
| | - Xue Wang
- School of Public Health, Institute of Epidemiology and StatisticsLanzhou UniversityLanzhouGansuChina
| | - Minzhen Wang
- School of Public Health, Institute of Epidemiology and StatisticsLanzhou UniversityLanzhouGansuChina
| | - Desheng Zhang
- Workers' Hospital of Jinchuan Group Co. Ltd.JinchangGansuChina
| | - Yana Bai
- School of Public Health, Institute of Epidemiology and StatisticsLanzhou UniversityLanzhouGansuChina
| | - Chun Yin
- Workers' Hospital of Jinchuan Group Co. Ltd.JinchangGansuChina
| | - Min Jiang
- Wuwei People's HospitalWuweiGansuChina
| | - Shan Zheng
- School of Public Health, Institute of Epidemiology and StatisticsLanzhou UniversityLanzhouGansuChina
| |
Collapse
|
2
|
Dikalov S, Panov A, Dikalova A. Critical Role of Mitochondrial Fatty Acid Metabolism in Normal Cell Function and Pathological Conditions. Int J Mol Sci 2024; 25:6498. [PMID: 38928204 PMCID: PMC11203650 DOI: 10.3390/ijms25126498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2024] [Revised: 06/07/2024] [Accepted: 06/09/2024] [Indexed: 06/28/2024] Open
Abstract
There is a "popular" belief that a fat-free diet is beneficial, supported by the scientific dogma indicating that high levels of fatty acids promote many pathological metabolic, cardiovascular, and neurodegenerative conditions. This dogma pressured scientists not to recognize the essential role of fatty acids in cellular metabolism and focus on the detrimental effects of fatty acids. In this work, we critically review several decades of studies and recent publications supporting the critical role of mitochondrial fatty acid metabolism in cellular homeostasis and many pathological conditions. Fatty acids are the primary fuel source and essential cell membrane building blocks from the origin of life. The essential cell membranes phospholipids were evolutionarily preserved from the earlier bacteria in human subjects. In the past century, the discovery of fatty acid metabolism was superseded by the epidemic growth of metabolic conditions and cardiovascular diseases. The association of fatty acids and pathological conditions is not due to their "harmful" effects but rather the result of impaired fatty acid metabolism and abnormal lifestyle. Mitochondrial dysfunction is linked to impaired metabolism and drives multiple pathological conditions. Despite metabolic flexibility, the loss of mitochondrial fatty acid oxidation cannot be fully compensated for by other sources of mitochondrial substrates, such as carbohydrates and amino acids, resulting in a pathogenic accumulation of long-chain fatty acids and a deficiency of medium-chain fatty acids. Despite popular belief, mitochondrial fatty acid oxidation is essential not only for energy-demanding organs such as the heart, skeletal muscle, and kidneys but also for metabolically "inactive" organs such as endothelial and epithelial cells. Recent studies indicate that the accumulation of long-chain fatty acids in specific organs and tissues support the impaired fatty acid oxidation in cell- and tissue-specific fashion. This work, therefore, provides a basis to challenge these established dogmas and articulate the need for a paradigm shift from the "pathogenic" role of fatty acids to the critical role of fatty acid oxidation. This is important to define the causative role of impaired mitochondrial fatty acid oxidation in specific pathological conditions and develop novel therapeutic approaches targeting mitochondrial fatty acid metabolism.
Collapse
Affiliation(s)
- Sergey Dikalov
- Division of Clinical Pharmacology, Vanderbilt University Medical Center, 2220 Pierce Ave, PRB 554, Nashville, TN 37232, USA; (A.P.); (A.D.)
| | | | | |
Collapse
|
3
|
Pourmal S, Green E, Bajaj R, Chemmama IE, Knudsen GM, Gupta M, Sali A, Cheng Y, Craik CS, Kroetz DL, Stroud RM. Structural basis of prostaglandin efflux by MRP4. Nat Struct Mol Biol 2024; 31:621-632. [PMID: 38216659 PMCID: PMC11145372 DOI: 10.1038/s41594-023-01176-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Accepted: 11/07/2023] [Indexed: 01/14/2024]
Abstract
Multidrug resistance protein 4 (MRP4) is a broadly expressed ATP-binding cassette transporter that is unique among the MRP subfamily for transporting prostanoids, a group of signaling molecules derived from unsaturated fatty acids. To better understand the basis of the substrate selectivity of MRP4, we used cryogenic-electron microscopy to determine six structures of nanodisc-reconstituted MRP4 at various stages throughout its transport cycle. Substrate-bound structures of MRP4 in complex with PGE1, PGE2 and the sulfonated-sterol DHEA-S reveal a common binding site that accommodates a diverse set of organic anions and suggest an allosteric mechanism for substrate-induced enhancement of MRP4 ATPase activity. Our structure of a catalytically compromised MRP4 mutant bound to ATP-Mg2+ is outward-occluded, a conformation previously unobserved in the MRP subfamily and consistent with an alternating-access transport mechanism. Our study provides insights into the endogenous function of this versatile efflux transporter and establishes a basis for MRP4-targeted drug design.
Collapse
Affiliation(s)
- Sergei Pourmal
- Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA
- Program in Chemistry and Chemical Biology, University of California, San Francisco, CA, USA
- Genentech, South San Francisco, CA, USA
| | - Evan Green
- Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA
- Biophysics Graduate Program, University of California, San Francisco, CA, USA
- Exelixis, Alameda, CA, USA
| | - Ruchika Bajaj
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA
| | - Ilan E Chemmama
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA
- Brightseed, South San Francisco, CA, USA
| | - Giselle M Knudsen
- Quantitative Biosciences Institute, University of California, San Francisco, CA, USA
| | - Meghna Gupta
- Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA
| | - Andrej Sali
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA
- Quantitative Biosciences Institute, University of California, San Francisco, CA, USA
- Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA
| | - Yifan Cheng
- Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA
- Howard Hughes Medical Institute, University of California, San Francisco, CA, USA
| | - Charles S Craik
- Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA
| | - Deanna L Kroetz
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
| | - Robert M Stroud
- Department of Biochemistry and Biophysics, University of California, San Francisco, CA, USA.
| |
Collapse
|
4
|
Wang Y, Sun Z, Zang G, Zhang L, Wang Z. Role of ceramides in diabetic foot ulcers (Review). Int J Mol Med 2023; 51:26. [PMID: 36799149 PMCID: PMC9943538 DOI: 10.3892/ijmm.2023.5229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Accepted: 01/20/2023] [Indexed: 02/09/2023] Open
Abstract
Diabetes mellitus (DM) is a metabolic disorder, which if not managed properly, can lead to serious health problems over time and impose significant financial burden on the patient, their family and society as a whole. The study of this disease and the underlying biological mechanism is gaining momentum. Multiple pieces of conclusive evidence show that ceramides are involved in the occurrence and development of diabetes. The present review focuses on the function of ceramides, a type of sphingolipid signaling molecule, to provide a brief description of ceramides and their metabolism, discuss the significant roles of ceramides in the healthy skin barrier, and speculate on the potential involvement of ceramides in the pathogenesis and development of diabetic foot ulcers (DFUs). Understanding these aspects of this disease more thoroughly is crucial to establish how ceramides contribute to the etiology of diabetic foot infections and identify possible therapeutic targets for the treatment of DFUs.
Collapse
Affiliation(s)
| | | | | | | | - Zhongqun Wang
- Correspondence to: Dr Zhongqun Wang, Department of Cardiology, Affiliated Hospital of Jiangsu University, 438 Jiefang Road, Jingkou, Zhenjiang, Jiangsu 212001, P.R. China, E-mail:
| |
Collapse
|
5
|
Dalle C, Tournayre J, Mainka M, Basiak-Rasała A, Pétéra M, Lefèvre-Arbogast S, Dalloux-Chioccioli J, Deschasaux-Tanguy M, Lécuyer L, Kesse-Guyot E, Fezeu LK, Hercberg S, Galan P, Samieri C, Zatońska K, Calder PC, Fiil Hjorth M, Astrup A, Mazur A, Bertrand-Michel J, Schebb NH, Szuba A, Touvier M, Newman JW, Gladine C. The Plasma Oxylipin Signature Provides a Deep Phenotyping of Metabolic Syndrome Complementary to the Clinical Criteria. Int J Mol Sci 2022; 23:ijms231911688. [PMID: 36232991 PMCID: PMC9570185 DOI: 10.3390/ijms231911688] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 09/23/2022] [Accepted: 09/24/2022] [Indexed: 11/06/2022] Open
Abstract
Metabolic syndrome (MetS) is a complex condition encompassing a constellation of cardiometabolic abnormalities. Oxylipins are a superfamily of lipid mediators regulating many cardiometabolic functions. Plasma oxylipin signature could provide a new clinical tool to enhance the phenotyping of MetS pathophysiology. A high-throughput validated mass spectrometry method, allowing for the quantitative profiling of over 130 oxylipins, was applied to identify and validate the oxylipin signature of MetS in two independent nested case/control studies involving 476 participants. We identified an oxylipin signature of MetS (coined OxyScore), including 23 oxylipins and having high performances in classification and replicability (cross-validated AUCROC of 89%, 95% CI: 85–93% and 78%, 95% CI: 72–85% in the Discovery and Replication studies, respectively). Correlation analysis and comparison with a classification model incorporating the MetS criteria showed that the oxylipin signature brings consistent and complementary information to the clinical criteria. Being linked with the regulation of various biological processes, the candidate oxylipins provide an integrative phenotyping of MetS regarding the activation and/or negative feedback regulation of crucial molecular pathways. This may help identify patients at higher risk of cardiometabolic diseases. The oxylipin signature of patients with metabolic syndrome enhances MetS phenotyping and may ultimately help to better stratify the risk of cardiometabolic diseases.
Collapse
Affiliation(s)
- Céline Dalle
- UNH, INRAE, Université Clermont Auvergne, 63000 Clermont-Ferrand, France
| | - Jérémy Tournayre
- UNH, INRAE, Université Clermont Auvergne, 63000 Clermont-Ferrand, France
| | - Malwina Mainka
- Faculty of Mathematics and Natural Sciences, University of Wuppertal, 42119 Wuppertal, Germany
| | - Alicja Basiak-Rasała
- Department of Social Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland
| | - Mélanie Pétéra
- Plateforme d’Exploration du Métabolisme, MetaboHUB Clermont, UNH, INRAE, Université Clermont Auvergne, 63000 Clermont-Ferrand, France
| | - Sophie Lefèvre-Arbogast
- Bordeaux Population Health Research Center, Université de Bordeaux, INSERMUMR 1219, 33076 Bordeaux, France
| | - Jessica Dalloux-Chioccioli
- MetaToul, MetaboHUB, Inserm/UPS UMR 1048-I2MC, Institut des Maladies Métaboliques et Cardiovasculaires, 31400 Toulouse, France
| | - Mélanie Deschasaux-Tanguy
- Nutritional Epidemiology Research Team (EREN), Sorbonne Paris Nord University, INSERM U1153, INRAE U1125, Cnam, Epidemiology and Statistics Research Center, University Paris Cité (CRESS), 93017 Bobigny, France
| | - Lucie Lécuyer
- Nutritional Epidemiology Research Team (EREN), Sorbonne Paris Nord University, INSERM U1153, INRAE U1125, Cnam, Epidemiology and Statistics Research Center, University Paris Cité (CRESS), 93017 Bobigny, France
| | - Emmanuelle Kesse-Guyot
- Nutritional Epidemiology Research Team (EREN), Sorbonne Paris Nord University, INSERM U1153, INRAE U1125, Cnam, Epidemiology and Statistics Research Center, University Paris Cité (CRESS), 93017 Bobigny, France
| | - Léopold K. Fezeu
- Nutritional Epidemiology Research Team (EREN), Sorbonne Paris Nord University, INSERM U1153, INRAE U1125, Cnam, Epidemiology and Statistics Research Center, University Paris Cité (CRESS), 93017 Bobigny, France
| | - Serge Hercberg
- Nutritional Epidemiology Research Team (EREN), Sorbonne Paris Nord University, INSERM U1153, INRAE U1125, Cnam, Epidemiology and Statistics Research Center, University Paris Cité (CRESS), 93017 Bobigny, France
| | - Pilar Galan
- Nutritional Epidemiology Research Team (EREN), Sorbonne Paris Nord University, INSERM U1153, INRAE U1125, Cnam, Epidemiology and Statistics Research Center, University Paris Cité (CRESS), 93017 Bobigny, France
| | - Cécilia Samieri
- Bordeaux Population Health Research Center, Université de Bordeaux, INSERMUMR 1219, 33076 Bordeaux, France
| | - Katarzyna Zatońska
- Department of Social Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland
| | - Philip C. Calder
- Faculty of Medicine, School of Human Development and Health, University of Southampton, Southampton SO16 6YD, UK
- NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton SO16 6YD, UK
| | - Mads Fiil Hjorth
- Obesity and Nutritional Sciences, Novo Nordisk Foundation, 2900 Hellerup, Denmark
| | - Arne Astrup
- Obesity and Nutritional Sciences, Novo Nordisk Foundation, 2900 Hellerup, Denmark
| | - André Mazur
- UNH, INRAE, Université Clermont Auvergne, 63000 Clermont-Ferrand, France
| | - Justine Bertrand-Michel
- MetaToul, MetaboHUB, Inserm/UPS UMR 1048-I2MC, Institut des Maladies Métaboliques et Cardiovasculaires, 31400 Toulouse, France
| | - Nils Helge Schebb
- Faculty of Mathematics and Natural Sciences, University of Wuppertal, 42119 Wuppertal, Germany
| | - Andrzej Szuba
- Department of Angiology, Hypertension and Diabetology, Wroclaw Medical University, 50-556 Wroclaw, Poland
| | - Mathilde Touvier
- Nutritional Epidemiology Research Team (EREN), Sorbonne Paris Nord University, INSERM U1153, INRAE U1125, Cnam, Epidemiology and Statistics Research Center, University Paris Cité (CRESS), 93017 Bobigny, France
| | - John W. Newman
- Obesity and Metabolism Research Unit, United States Department of Agriculture, Agricultural Research Service, Western Human Nutrition Research Center, Davis, CA 95616, USA
- University of California Davis Genome Center, University of California, Davis, CA 95616, USA
- Department of Nutrition, University of California, Davis, CA 95616, USA
| | - Cécile Gladine
- UNH, INRAE, Université Clermont Auvergne, 63000 Clermont-Ferrand, France
- Correspondence: ; Tel.: +33-473-624-230
| |
Collapse
|
6
|
Paraoxonase 1 hydrolysis of EPA-derived lactone impairs endothelial-mediated vasodilation. Prostaglandins Other Lipid Mediat 2022; 162:106665. [PMID: 35817276 DOI: 10.1016/j.prostaglandins.2022.106665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 06/26/2022] [Accepted: 07/07/2022] [Indexed: 11/20/2022]
Abstract
Human serum paraoxonase-1 (PON1) is a lactonase that plays a significant role in anti-atherosclerotic high-density lipoprotein (HDL) activity. PON1 is also localized in endothelial cell membranes, where it is enzymatically active and regulates endothelial signals. PON1 has a high specificity for lipophilic lactones and has been shown to hydrolyze and regulate lactone lipid mediators derived from arachidonic polyunsaturated fatty acids (PUFA). Previously, we showed that an arachidonic acid lactone metabolite (AA-L) dose-dependently dilates PON1 gene deletion (PON1KO) mouse mesenteric arteries significantly more than wild-type arteries. In contrast, preincubation with HDL or rePON1 reduced AA-L-dependent vasodilation. Recently we showed that an additional δ-lactone metabolite derived from the eicosapentaenoic acid lactone, 5,6-δ-DiHETE lactone (EPA-L) reduced blood pressure by dilating microvessels of hypertensive rats. However, whether PON1 regulates the activity of the EPA-L lipid mediator is unknown. AIM To demonstrate that PON1 hydrolyzes EPA-L and to reveal the effect of this hydrolysis on endothelial-dependent vascular dilation. METHODS AND RESULTS In vascular reactivity experiments, EPA-L dose-dependently dilated PON1KO mouse mesenteric arteries significantly more than wild-type mesenteric arteries. This dilation was not affected by nitric oxide inhibition. PON1 impaired the cellular calcium increase mediated by EPA-L in endothelial cells, though this impairment decreased with PON1 internalization to the cell. CONCLUSION These findings support that PUFA-lactones are physiological substrates of PON1, and that PON1 activity in the endothelial membrane affects the dilation of microvessels that is induced by these endothelial-derived hyperpolarizing PUFA-lactones.
Collapse
|
7
|
Craps S, Van Wauwe J, De Moudt S, De Munck D, Leloup AJ, Boeckx B, Vervliet T, Dheedene W, Criem N, Geeroms C, Jones EA, Zwijsen A, Lambrechts D, Fransen P, Beerens M, Luttun A. Prdm16 Supports Arterial Flow Recovery by Maintaining Endothelial Function. Circ Res 2021; 129:63-77. [PMID: 33902304 PMCID: PMC8221541 DOI: 10.1161/circresaha.120.318501] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 03/30/2021] [Accepted: 04/26/2021] [Indexed: 02/07/2023]
Abstract
[Figure: see text].
Collapse
MESH Headings
- Animals
- Aorta/metabolism
- Aorta/physiopathology
- Calcium/metabolism
- Calcium Signaling
- Cells, Cultured
- Collateral Circulation
- DNA-Binding Proteins/genetics
- DNA-Binding Proteins/metabolism
- Disease Models, Animal
- Endothelial Cells/metabolism
- Endothelium, Vascular/metabolism
- Endothelium, Vascular/physiopathology
- Femoral Artery/metabolism
- Femoral Artery/physiopathology
- Hindlimb/blood supply
- Ischemia/genetics
- Ischemia/metabolism
- Ischemia/physiopathology
- Male
- Mice, Inbred C57BL
- Mice, Knockout
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/physiopathology
- Myocytes, Smooth Muscle/metabolism
- Neovascularization, Physiologic
- Regional Blood Flow
- Transcription Factors/genetics
- Transcription Factors/metabolism
- Mice
Collapse
Affiliation(s)
- Sander Craps
- Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology (S.C., J.V.W., W.D., N.C., E.A.V.J., A.Z., M.B., A.L.), KU Leuven, Leuven, Belgium
| | - Jore Van Wauwe
- Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology (S.C., J.V.W., W.D., N.C., E.A.V.J., A.Z., M.B., A.L.), KU Leuven, Leuven, Belgium
| | - Sofie De Moudt
- Pharmaceutical Sciences, Physiopharmacology, University of Antwerp, Antwerp, Belgium (S.D.M., D.D.M., A.J.A.L., P.F.)
| | - Dorien De Munck
- Pharmaceutical Sciences, Physiopharmacology, University of Antwerp, Antwerp, Belgium (S.D.M., D.D.M., A.J.A.L., P.F.)
| | - Arthur J.A. Leloup
- Pharmaceutical Sciences, Physiopharmacology, University of Antwerp, Antwerp, Belgium (S.D.M., D.D.M., A.J.A.L., P.F.)
| | - Bram Boeckx
- Laboratory for Translational Genetics, Department of Human Genetics (B.B., D.L.), KU Leuven, Leuven, Belgium
- VIB Center for Cancer Biology, Leuven, Belgium (B.B., D.L.)
| | - Tim Vervliet
- Laboratory of Molecular and Cellular Signaling, Department of Cellular and Molecular Medicine (T.V.), KU Leuven, Leuven, Belgium
| | - Wouter Dheedene
- Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology (S.C., J.V.W., W.D., N.C., E.A.V.J., A.Z., M.B., A.L.), KU Leuven, Leuven, Belgium
| | - Nathan Criem
- Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology (S.C., J.V.W., W.D., N.C., E.A.V.J., A.Z., M.B., A.L.), KU Leuven, Leuven, Belgium
| | - Carla Geeroms
- Prometheus, Division of Skeletal Tissue Engineering (C.G.), KU Leuven, Leuven, Belgium
- Skeletal Biology and Engineering Research Center, Department of Development and Regeneration (C.G.), KU Leuven, Leuven, Belgium
| | - Elizabeth A.V. Jones
- Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology (S.C., J.V.W., W.D., N.C., E.A.V.J., A.Z., M.B., A.L.), KU Leuven, Leuven, Belgium
| | - An Zwijsen
- Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology (S.C., J.V.W., W.D., N.C., E.A.V.J., A.Z., M.B., A.L.), KU Leuven, Leuven, Belgium
| | - Diether Lambrechts
- Laboratory for Translational Genetics, Department of Human Genetics (B.B., D.L.), KU Leuven, Leuven, Belgium
- VIB Center for Cancer Biology, Leuven, Belgium (B.B., D.L.)
| | - Paul Fransen
- Pharmaceutical Sciences, Physiopharmacology, University of Antwerp, Antwerp, Belgium (S.D.M., D.D.M., A.J.A.L., P.F.)
| | - Manu Beerens
- Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology (S.C., J.V.W., W.D., N.C., E.A.V.J., A.Z., M.B., A.L.), KU Leuven, Leuven, Belgium
- Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA (M.B.)
| | - Aernout Luttun
- Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology (S.C., J.V.W., W.D., N.C., E.A.V.J., A.Z., M.B., A.L.), KU Leuven, Leuven, Belgium
| |
Collapse
|
8
|
Xue J, Wang Y, Li B, Yu S, Wang A, Wang W, Gao Z, Tang X, Yan L, Wan Q, Qin G, Chen L, Ning G, Mu Y. Triglycerides to high-density lipoprotein cholesterol ratio is superior to triglycerides and other lipid ratios as an indicator of increased urinary albumin-to-creatinine ratio in the general population of China: a cross-sectional study. Lipids Health Dis 2021; 20:13. [PMID: 33588849 PMCID: PMC7883433 DOI: 10.1186/s12944-021-01442-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2020] [Accepted: 02/02/2021] [Indexed: 11/13/2022] Open
Abstract
Background Dyslipidemia contributes to the pathogenesis of renal dysfunction. Previous research demonstrated that triglycerides (TG), instead of other individual lipid indexes, has a significant link with elevated urinary albumin-to-creatinine ratio (UACR). However, it is unclear whether lipid ratios are superior indicators of increased UACR compared with TG. This research is to determine whether there are close relationships of lipid ratios with UACR in a general population. Methods 35,751 participants from seven centers across China were enrolled. UACR equal or higher than 30 mg/g was recognized as increased albuminuria. The associations of TG, low-density lipoprotein cholesterol (LDL-C)/ high-density lipoprotein cholesterol (HDL-C), TG/HDL-C and non-high-density lipoprotein cholesterol (non-HDL-C)/HDL-C with increased UACR were evaluated by linear and logistic regression analyses in females and males separately. Results There were 3692 (14.8%) female subjects, and 1307 (12.0%) male subjects characterized as having increased UACR. There were significantly differences in TG/HDL-C and non-HDL-C/HDL-C between the normal UACR group and the increased UACR group, while LDL-C/HDL-C was not. Furthermore, linear regression analysis was implemented and showed that TG and TG/HDL-C were both positively related to UACR even after a variety of potential confounders were adjusted regardless of sexes, while the correlation between non-HDL-C/HDL-C and elevated UACR were only significant in females. Further analyses utilizing logistic regression demonstrated that compared with non-HDL-C/HDL-C and TG, TG/HDL-C showed the strongest association with increased UACR (quartile 1 of TG/HDL-C as a reference; OR [95% CI] of quartile 4: 1.28 [1.13–1.44] in women, 1.24 [1.02–1.50] in men) after fully adjusting for potential confounding factors. Stratified analyses revealed that in males who were overweight and in females who were overweight or over 55 years or had prediabetes or prehypertension, TG/HDL-C had significant associations with abnormal UACR. Conclusions Compared with TG and other routine lipid ratios, TG/HDL-C is a superior indicator for increased UACR. Supplementary Information The online version contains supplementary material available at 10.1186/s12944-021-01442-8.
Collapse
Affiliation(s)
- Jing Xue
- Medical School of Chinese PLA, Beijing, China.,Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, No.28 Fuxing Road, Haidian district, Beijing, 100853, China
| | - Yuxia Wang
- Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, No.28 Fuxing Road, Haidian district, Beijing, 100853, China
| | - Bing Li
- Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, No.28 Fuxing Road, Haidian district, Beijing, 100853, China
| | - Songyan Yu
- Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, No.28 Fuxing Road, Haidian district, Beijing, 100853, China
| | - Anping Wang
- Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, No.28 Fuxing Road, Haidian district, Beijing, 100853, China
| | - Weiqing Wang
- Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China
| | - Zhengnan Gao
- Center Hospital of Dalian, Dalian, Liaoning, China
| | - Xulei Tang
- First Hospital of Lanzhou University, Lanzhou, Gansu, China
| | - Li Yan
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
| | - Qin Wan
- Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan, China
| | - Guijun Qin
- Zhengzhou University First affiliated Hospital, Zhengzhou, Henan, China
| | - Lulu Chen
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Guang Ning
- Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China
| | - Yiming Mu
- Medical School of Chinese PLA, Beijing, China. .,Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, No.28 Fuxing Road, Haidian district, Beijing, 100853, China.
| |
Collapse
|
9
|
Wasserman AH, Venkatesan M, Aguirre A. Bioactive Lipid Signaling in Cardiovascular Disease, Development, and Regeneration. Cells 2020; 9:E1391. [PMID: 32503253 PMCID: PMC7349721 DOI: 10.3390/cells9061391] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 05/23/2020] [Accepted: 06/01/2020] [Indexed: 12/13/2022] Open
Abstract
Cardiovascular disease (CVD) remains a leading cause of death globally. Understanding and characterizing the biochemical context of the cardiovascular system in health and disease is a necessary preliminary step for developing novel therapeutic strategies aimed at restoring cardiovascular function. Bioactive lipids are a class of dietary-dependent, chemically heterogeneous lipids with potent biological signaling functions. They have been intensively studied for their roles in immunity, inflammation, and reproduction, among others. Recent advances in liquid chromatography-mass spectrometry techniques have revealed a staggering number of novel bioactive lipids, most of them unknown or very poorly characterized in a biological context. Some of these new bioactive lipids play important roles in cardiovascular biology, including development, inflammation, regeneration, stem cell differentiation, and regulation of cell proliferation. Identifying the lipid signaling pathways underlying these effects and uncovering their novel biological functions could pave the way for new therapeutic strategies aimed at CVD and cardiovascular regeneration.
Collapse
Affiliation(s)
- Aaron H. Wasserman
- Regenerative Biology and Cell Reprogramming Laboratory, Institute for Quantitative Health Science and Engineering (IQ), Michigan State University, East Lansing, MI 48824, USA; (A.H.W.); (M.V.)
- Department of Biomedical Engineering, College of Engineering, Michigan State University, East Lansing, MI 48824, USA
| | - Manigandan Venkatesan
- Regenerative Biology and Cell Reprogramming Laboratory, Institute for Quantitative Health Science and Engineering (IQ), Michigan State University, East Lansing, MI 48824, USA; (A.H.W.); (M.V.)
- Department of Biomedical Engineering, College of Engineering, Michigan State University, East Lansing, MI 48824, USA
| | - Aitor Aguirre
- Regenerative Biology and Cell Reprogramming Laboratory, Institute for Quantitative Health Science and Engineering (IQ), Michigan State University, East Lansing, MI 48824, USA; (A.H.W.); (M.V.)
- Department of Biomedical Engineering, College of Engineering, Michigan State University, East Lansing, MI 48824, USA
| |
Collapse
|